Compare VOYA & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | BLCO |
|---|---|---|
| Founded | 1975 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Life Insurance | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.0B |
| IPO Year | 2013 | 2022 |
| Metric | VOYA | BLCO |
|---|---|---|
| Price | $73.71 | $16.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 14 |
| Target Price | ★ $83.67 | $17.31 |
| AVG Volume (30 Days) | ★ 820.5K | 408.9K |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.82 | N/A |
| Revenue | ★ $8,088,000,000.00 | $4,976,000,000.00 |
| Revenue This Year | N/A | $8.08 |
| Revenue Next Year | $5.02 | $5.77 |
| P/E Ratio | $12.66 | ★ N/A |
| Revenue Growth | 2.91 | ★ 6.23 |
| 52 Week Low | $52.43 | $10.45 |
| 52 Week High | $78.00 | $18.99 |
| Indicator | VOYA | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 60.98 |
| Support Level | $69.47 | $16.39 |
| Resistance Level | $71.78 | $17.41 |
| Average True Range (ATR) | 1.46 | 0.46 |
| MACD | 0.55 | 0.06 |
| Stochastic Oscillator | 77.55 | 72.71 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.